News > BiondVax announces pricing of $8 million underwritten public offering
BiondVax announces pricing of $8 million underwritten public offering
16/12/2022 09:43 PM | Click to read full article
BiondVax Pharmaceuticals Ltd. which focuses on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced the pricing of its underwritten public offering with gross proceeds to the Company expected to be approximately $8,000,000, before deducting underwriting discounts and other expenses payable by the Company.
